Equities Analysts Issue Forecasts for iBio FY2027 Earnings

Key Points

• Brookline Capital Markets raised its FY2027 EPS forecast for iBio to a loss of $0.29 per share from a projected loss of $0.31; its Q4 2027 estimate is a loss of $0.09 per share.
• iBio reported a quarterly loss of $0.05 per share, beating the $0.07 loss analysts expected, and revenue of $1.07 million versus estimates of $0.03 million.
• Analyst sentiment is mixed: MarketBeat reports a consensus “Buy” rating and $6 price target, while the shares opened at $0.76 and have traded between $0.69 and $3.82 over the past year.

iBio, Inc. (NASDAQ:IBIO - Free Report) - Investment analysts at Brookline Capital Markets increased their FY2027 earnings per share (EPS) estimates for iBio in a note issued to investors on Tuesday, November 10th. Brookline Capital Markets analyst K. Dolliver now expects that the company will post earnings per share of ($0.29) for the year, up from their prior estimate of ($0.31). The consensus estimate for iBio's current full-year earnings is ($0.39) per share. Brookline Capital Markets also issued estimates for iBio's Q4 2027 earnings at ($0.09) EPS.

IBIO has been the subject of several other reports. Wall Street Zen cut shares of iBio from a "hold" rating to a "sell" rating in a research report on Sunday, September 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of iBio in a research note on Monday, September 21st. Finally, HC Wainwright started coverage on shares of iBio in a report on Thursday, September 17th. They set a "buy" rating and a $7.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $6.00.

iBio Price Performance

NASDAQ:IBIO opened at $0.76 on Friday. iBio has a one year low of $0.69 and a one year high of $3.82. The company has a market cap of $49.01 million, a PE ratio of -2.72 and a beta of 1.47. The firm's 50 day simple moving average is $0.99 and its 200 day simple moving average is $1.63.

iBio (NASDAQ:IBIO - Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $0.03 million.

Institutional Trading of iBio

Institutional investors have recently added to or reduced their stakes in the stock. Affinity Asset Advisors LLC raised its holdings in iBio by 51.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,107,200 shares of the company's stock worth $5,904,000 after purchasing an additional 1,050,000 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of iBio in the 2nd quarter valued at $873,000. ADAR1 Capital Management LLC boosted its stake in shares of iBio by 15.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 469,878 shares of the company's stock valued at $893,000 after purchasing an additional 64,347 shares during the last quarter. Walleye Capital LLC boosted its stake in shares of iBio by 95.9% in the 1st quarter. Walleye Capital LLC now owns 388,554 shares of the company's stock valued at $738,000 after purchasing an additional 190,179 shares during the last quarter. Finally, Noesis Capital Mangement Corp boosted its stake in shares of iBio by 38.9% in the 1st quarter. Noesis Capital Mangement Corp now owns 311,500 shares of the company's stock valued at $592,000 after purchasing an additional 87,300 shares during the last quarter. 7.90% of the stock is currently owned by institutional investors.

iBio Company Profile

iBio, Inc. NASDAQ: IBIO is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify and optimize antibody candidates for potential use in cancer and other serious diseases. iBio's discovery capabilities are built around proprietary antibody-design and profiling technologies, including platforms intended to improve the speed and quality of therapeutic antibody development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.